Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 206

1.

[Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].

Tamura H.

Rinsho Ketsueki. 2018;59(10):2169-2177. doi: 10.11406/rinketsu.59.2169. Japanese.

PMID:
30305523
2.

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.

Chehab S, Zhang C, Panjic EH, Chen Z, Kaufman JL, Lonial S, Nooka A, Harvey RD.

Cancer. 2018 Oct 10. doi: 10.1002/cncr.31746. [Epub ahead of print]

PMID:
30303526
3.

Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

Lamb YN.

Drugs. 2018 Sep;78(14):1481-1488. doi: 10.1007/s40265-018-0969-4.

PMID:
30232695
4.

Practical Considerations for Antibodies in Myeloma.

Laubach JP, van de Donk N, Davies FE, Mikhael J.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):667-674. doi: 10.1200/EDBK_205443.

5.

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial.

Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG.

Cancer. 2018 Sep 11. doi: 10.1002/cncr.31680. [Epub ahead of print]

PMID:
30204239
6.

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.

Cella D, McKendrick J, Kudlac A, Palumbo A, Oukessou A, Vij R, Zyczynski T, Davis C.

Ann Hematol. 2018 Sep 4. doi: 10.1007/s00277-018-3469-4. [Epub ahead of print]

PMID:
30178193
7.

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Cho SF, Anderson KC, Tai YT.

Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018. Review.

8.

Carfilzomib.

Engelhardt M, Szymaniak-Vits M, Ajayi S, Dold SM, Müller SJ, Scheubeck S, Wäsch R.

Recent Results Cancer Res. 2018;212:265-283. doi: 10.1007/978-3-319-91439-8_13.

PMID:
30069635
9.

Pomalidomide.

Engelhardt M, Ajayi S, Reinhardt H, Müller SJ, Dold SM, Wäsch R.

Recent Results Cancer Res. 2018;212:169-185. doi: 10.1007/978-3-319-91439-8_8.

PMID:
30069630
10.

The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.

Abramson HN.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):611-627. doi: 10.1016/j.clml.2018.06.015. Epub 2018 Jun 18. Review.

11.

Elotuzumab.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

12.

Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.

Nooka AK, Gleason C, Sargeant MO, Walker M, Watson M, Panjic EH, Lonial S.

J Oncol Pract. 2018 Jul;14(7):414-422. doi: 10.1200/JOP.18.00143.

PMID:
29996069
13.

Maintenance and continuous therapy for multiple myeloma.

Richardson PG, Laubach J, Gandolfi S, Facon T, Weisel K, O'Gorman P.

Expert Rev Anticancer Ther. 2018 Aug;18(8):751-764. doi: 10.1080/14737140.2018.1490181. Epub 2018 Jul 3.

PMID:
29932776
14.
15.

[Multiple myeloma: update on pathophysiology and management].

Hanamura I, Iida S.

Rinsho Ketsueki. 2018;59(5):529-538. doi: 10.11406/rinketsu.59.529. Japanese.

PMID:
29877243
16.

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).

Jagannath S, Abonour R, Durie BGM, Gasparetto C, Hardin JW, Narang M, Terebelo HR, Toomey K, Wagner L, Srinivasan S, Kitali A, Yue L, Flick ED, Agarwal A, Rifkin RM.

Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):480-485.e3. doi: 10.1016/j.clml.2018.04.007. Epub 2018 May 4.

17.

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG.

Br J Haematol. 2018 Aug;182(4):495-503. doi: 10.1111/bjh.15384. Epub 2018 May 29.

18.

A look at treatment strategies for relapsed multiple myeloma.

Cetani G, Boccadoro M, Oliva S.

Expert Rev Anticancer Ther. 2018 Aug;18(8):735-750. doi: 10.1080/14737140.2018.1477594. Epub 2018 May 24.

PMID:
29768064
19.

The difficult business of assessing new therapies for smouldering multiple myeloma.

Zonder JA.

Br J Haematol. 2018 Aug;182(4):463-464. doi: 10.1111/bjh.15385. Epub 2018 May 16. No abstract available.

PMID:
29767407
20.

Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.

D'Agostino M, Gazzera G, Cetani G, Bringhen S, Boccadoro M, Gay F.

Curr Med Chem. 2018 May 13. doi: 10.2174/0929867325666180514114806. [Epub ahead of print]

PMID:
29756564

Supplemental Content

Loading ...
Support Center